SCHEMBL23536109

SCHEMBL23536109

COCS(=O)(=O)c1cccc(CS(=O)(=O)O)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.36
TNF P01375 1/20 0.36
RAB9A P51151 1/20 0.36
NOD1 Q9Y239 1/20 0.36
MAOB P27338 1/20 0.35
MAPT P10636 1/20 0.35
PTPRB P23467 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
ALDH1A1 P00352 2/20 0.35
GAA P10253 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HSD11B1 P28845 1/20 0.35
AKR1C3 P42330 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HTR6 P50406 1/20 0.34
CYP19A1 P11511 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23535981 0.86 NPC1 (0.36) NPC1TNFRAB9ANOD1MAOB
SCHEMBL29948591 0.84 CYP19A1 (0.35) NPC1TNFRAB9ANOD1MAOB
SCHEMBL29931794 0.82 TSHR (0.41) NPC1TNFRAB9ANOD1MAOB
SCHEMBL23536153 0.82 TSHR (0.41) NPC1TNFRAB9ANOD1MAOB
SCHEMBL23536115 0.81 MAOB (0.43) MAOBMAPTALDH1A1HSD17B10LMNA
SCHEMBL11413912 0.77 TSHR (0.53) NPC1TNFRAB9ANOD1ALDH1A1
SCHEMBL2932625 0.75 TAAR1 (0.51) MAPTALDH1A1SMN1; SMN2
SCHEMBL8075846 0.74 CA2 (0.41) MAPTALDH1A1GAASMN1; SMN2CYP19A1
SCHEMBL23536080 0.73 RAB9A (0.66) NPC1TNFRAB9ANOD1ALDH1A1
SCHEMBL6913653 0.73 PSIP1 (0.60) MAOBMAPTALDH1A1HSD17B10HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 US disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 NPC1 346/4885TNF 4750/4885RAB9A 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.